Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

HOVON supports clinical research in newly diagnosed and relapsed acute myeloid leukemia, including molecularly defined disease with NPM1, IDH1, IDH2, and FLT3 alterations. Its portfolio also includes myelodysplastic syndrome and MDS-EB2, with interest in treatment-resistant and unfit patient populations.

• Targeted therapy in molecularly defined AML
• Combination regimens for newly diagnosed disease
• Maintenance strategies in AML and MDS

Research activity in this area spans intensive and non-intensive treatment settings, with attention to remission depth, survival outcomes, and disease control in older or medically complex patients.